

WPI ACC NO: 1994-185172/199423

Sustained-release compsn. for hormone drugs, pref. LHRH antagonists, - contains biodegradable carboxyl-contg. polymer e.g. lactic acid glycolic acid copolymer, providing constant release of drug without initial burst

Patent Assignee: IGARI Y (IGAR-I); KAMEI S (KAME-I); OGAWA Y (OGAW-I); TAKEDA CHEM IND LTD (TAKE); TAKEDA PHARM CO LTD (TAKE); TAKEDA PHARM

IND CO LTD (TAKE); TAKEDA YAKUHIN KOGYO KK (TAKE)

Inventor: IGARI Y; KAMEI S; OGAWA Y; OGAWA T

Patent Family (42 patents, 35 countries)

Patent Application

Number	Kind	Date	Number	Kind	Date	Update
EP 601799	A1	19940615	EP 1993309681	A	19931203	199423 B
WO 1994013317	A1	19940623	WO 1993JP1773	A	19931207	199426 E
AU 199352113	A	19940616	AU 199352113	A	19931201	199429 E
NO 199304423	A	19940608	NO 19934423	A	19931206	199429 E
FI 199305471	A	19940608	FI 19935471	A	19931207	199431 E
CA 2110730	A	19940608	CA 2110730	A	19931206	199434 E
NZ 250349	A	19941222	NZ 250349	A	19931203	199505 E
JP 7097334	A	19950411	JP 1993306659	A	19931207	199523 E
ZA 199309163	A	19950830	ZA 19939163	A	19931207	199540 E
CN 1096221	A	19941214	CN 1993121140	A	19931207	199549 E
US 5480868	A	19960102	US 1993162698	A	19931207	199607 E
AU 669939	B	19960627	AU 199352113	A	19931201	199636 E
US 5668111	A	19970916	US 1993162698	A	19931207	199743 E
		US 1995471382		A	19950606	
SG 46283	A1	19980220	SG 19962095	A	19931203	199821 E
TW 333456	A	19980611	TW 1993109889	A	19931124	199844 E
US 5972891	A	19991026	US 1993162698	A	19931207	199952 E
		US 1995471382		A	19950606	
		US 1997892315		A	19970714	
RU 2128055	C1	19990327	RU 1995114533	A	19931207	200024 E
		WO 1993JP1773		A	19931207	
MX 195675	B	20000327	MX 19937686	A	19931206	200123 E
NO 200101930	A	19940608	NO 19934423	A	19931206	200138 NCE
		NO 20011930		A	20010419	
EP 601799	B1	20010808	EP 1993309681	A	19931203	200146 E
		EP 2000203850		A	19931203	
NO 310704	B1	20010820	NO 19934423	A	19931206	200154 E
KR 2001016379	A	20010305	KR 200051490	A	20000901	200157 E
DE 69330547	E	20010913	DE 69330547	A	19931203	200161 E
		EP 1993309681		A	19931203	
ES 2158856	T3	20010916	EP 1993309681	A	19931203	200164 E
KR 305951	B	20011130	KR 199326743	A	19931207	200246 E
KR 319425	B	20020109	KR 199326743	A	19931207	200253 E

	KR 200051490	A 20000901			
US 20020147150	A1 20021010	US 1993162698	A 19931207	200269	E
	US 1995471382	A 19950606			
	US 1997892315	A 19970714			
	US 1999386949	A 19990831			
	US 2000640983	A 20000818			
	US 200125967	A 20011226			
US 20020173467	A1 20021121	US 1993162698	A 19931207	200279	E
	US 1995471382	A 19950606			
	US 1997892315	A 19970714			
	US 1999386232	A 19990831			
	US 2002127558	A 20020423			
US 20030039698	A1 20030227	US 1997892315	A 19970714	200318	E
	US 1999386232	A 19990831			
US 6528093	B1 20030304	US 1993162698	A 19931207	200320	E
	US 1995471382	A 19950606			
	US 1997892315	A 19970714			
	US 1999386232	A 19990831			
FI 200300166	A 20030204	FI 19935471	A 19931207	200337	E
	FI 2003166	A 20030204			
CN 1428144	A 20030709	CN 1993121140	A 19931207	200363	E
	CN 2002108206	A 19931207			
PH 1199347385	B1 20020416	PH 199347385	A 19931203	200382	E
CN 1099893	C 20030129	CN 1993121140	A 19931207	200532	E
EP 1088555	B1 20050518	EP 1993309681	A 19931203	200538	E
	EP 2000203850	A 19931203			
FI 116196	B1 20051014	FI 19935471	A 19931207	200570	E
	FI 2003166	A 20030204			
JP 3725906	B2 20051214	JP 1993306659	A 19931207	200582	E
US 7048947	B2 20060523	US 1993162698	A 19931207	200635	E
	US 1995471382	A 19950606			
	US 1997892315	A 19970714			
	US 1999386232	A 19990831			
	US 2002127558	A 20020423			
NO 323428	B1 20070430	NO 19934423	A 19931206	200731	NCE
	NO 20011930	A 20010419			
CN 1911214	A 20070214	CN 200610099723	A 19931207	200740	E
PH 1200101399	B1 20060608	PH 199347385	A 19931203	200827	E
	PH 20011399	A 20010605			
CA 2110730	C 20080916	CA 2110730	A 19931206	200864	E

Priority Applications (no., kind, date): JP 1992327070 A 19921207; JP 199318978 A 19930205; JP 1993145134 A 19930616; JP 1993145134 A 19930618; NO 19934423 A 19931206; NO 20011930 A 20010419

Alerting Abstract EP A1

A sustained-release cpd. comprising a peptide of formula (I) and a biodegradable polymer with a terminal COOH gp. In the formulae, X = acyl; R1,R2,R4 = aromatic cyclic; R3 = D-amino acid residue or gp. of formula(i); R3' = heterocyclic; R5 = (CH<sub>2</sub>)<sub>n</sub>-R5', n = 2 or 3 R5' = amino (opt. substd.) aromatic cyclic or O-glycosyl; R6 = (CH<sub>2</sub>)<sub>n</sub>-R6', R6' = amino (opt. substd.); R7 = D-amino acid residue or azaglycyl residue; Q = H or lower alkyl (or their salts) and a biodegradable polymer with a terminal carboxyl gp.

Pref. X = 2-7C alkanoyl (opt. substd. by 5-6 membered heterocyclic carboximido), pref. 2-4C alkanoyl (opt. substd. by tetrahydrofuryl carboxamide) or more pref. acetyl; and the biodegradable polymer is a mixt. of a copolymer of glycolic acid and a cpd. HO - CHR - COOH (R = 2-8C alkyl) and a polylactic acid, or is a copolymer of lactic acid and glycolic acid.

USE/ADVANTAGE - (I) is a LHRH antagonist. It is useful to treat hormone-dependent diseases e.g. prostrate cancer, benign prostatomegaly, endometriosis, hysteromyoma, metrofibroma, precocious puberty, mammary cancer etc., or as contraceptives. The competitive inhibition of LHRH is persistent and the sustained-release prepn. shows a constant release of the peptide over a long time (1 - 3 months), without an initial burst. (I) has low toxicity and can be used in a wide range of mammals.